Cancer immunotherapy has made significant strides with the development of chimeric antigen receptor (CAR) T cell therapy—an innovative approach in which genetically engineered T cells are designed to recognize and attack tumor-associated antigens (TAAs) on cancer cells, independent of major histocompatibility complex (MHC) recognition. This evidence concerns the gene HLA-C and neoplasm.